AB1134 BIBLIOMETRIC NETWORK ANALYSIS ON TOCILIZUMAB TREATMENT FOR COVID-19 PATIENTS
Authors: L. Cascella, F. Monaco, D. Nocerino, A. Infernuso, V. Cascella, F. Del Prato, S. Cascella, M. Cascella
Journal: Annals of the Rheumatic Diseases (2022)

Background Tocilizumab is a humanized monoclonal antibody. It provokes inhibition of the proinflammatory signals by binding to IL-6 receptors [1]. Due to these properties, it is used in inflammatory arthritis conditions and in cytokine release syndromes [2]. Notably, given its ability to intercept proinflammatory cascades, tocilizumab is an important option for patients with critical forms of COVID-19 [3]. Nevertheless, several aspects about the use of tocilizumab in this clinical setting should be better explained [4]. Objectives This bibliometric analysis is aimed at dissecting the developed research in the subject. It could provide useful findings for predicting the direction of future studies, implementing corrective measures, and enhancing research networks. Methods The global literature on tocilizumab treatment for COVID-19 was scanned in the Web of Science (WOS) online database. The search terms applied to identify the closest matching articles included “tocilizumab” and “COVID-19”. All data were acquired on January 29, 2022. The information for the documents that met the requirements were extracted. The source was Journal Citation Reports™ 2020 (Clarivate Analytics). The literature analysis and knowledge visualization software tool VOSviewer (version 1.6.17) was used to analyze the co-occurrence of keywords (interconnection), co-citation (bibliographic coupling), co-citation analysis for sources, and countries, and analysis of the most productive organizations and networks. Results A total of 1019 articles on tocilizumab treatment for COVID-19 patients were published from 2020 to January 2022, in WOS. Of those: 462 in 2020, 546 in 2021, 11 on January 29, 2022. About article types, 697 were research articles, 322 reviews. The analysis of keywords provided by authors showed that of 50 keywords, 17 met the threshold (interconnection 2). The most frequent keywords were EFFICACY, and OFF-LABEL USE (Figure 1) Figure 1. Co-occurrence of keywords For the co-citation study, we used cited sources (journals) as unit (minimum numbers of citations of a source 1, maximum 3). Of 45 sources, 27 met the threshold. For each source, the total strength of the co-citation links with other sources was rated. The minimum number of documents per country was 2. Thus, 23 countries met the threshold. The largest number of partnerships regarded the US, and Italy. The analysis of affiliations was conducted by considering the cut-off 1 and 5 as the minimum and maximum number of documents. Out of 151 organizations, 94 met the threshold. Conclusion This bibliometric network analysis on tocilizumab treatment for COVID-19 patients can be useful for planning future research. It highlights the strength of representative scholars and core research teams. Additional networks should be built, and high-value clinical studies are needed. References [1]Sebba A. Tocilizumab: The first interleukin-6-receptor inhibitor. Am J Health Syst Pharm 2008;65:1413–1418 [2]Tanaka T, Narazaki M, Ogata A, et al. A New Era for the Treatment of Inflammatory Autoimmune Diseases by Interleukin-6 Blockade Strategy. Semin Immunol 2014;26:88–96 [3]Maraolo AE, Crispo A, Piezzo M, et al. The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies. J Clin Med 2021;10:4935 [4]Ascierto PA, Fu B, Wei H. IL-6 modulation for COVID-19: the right patients at the right time? J Immunother Cancer 2021;9:e002285 Disclosure of Interests None declared